维格列汀相关大疱性类天疱疮病例系列-罕见的副作用。

IF 1.5 4区医学 Q2 Medicine

the Indian Journal of Pharmacy Pub Date : 2025-09-01 Epub Date: 2025-08-22 DOI:10.4103/ijp.ijp_522_24

Mohit Kumar Shahi, J V Ashwin, Astha Singh, Suvrat Gupta, K Surya

{"title":"维格列汀相关大疱性类天疱疮病例系列-罕见的副作用。","authors":"Mohit Kumar Shahi, J V Ashwin, Astha Singh, Suvrat Gupta, K Surya","doi":"10.4103/ijp.ijp_522_24","DOIUrl":null,"url":null,"abstract":"Vildagliptin, among the most commonly used, OHA, belongs to group dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus, has recently been associated with bullous pemphigoid, characterized by fluid-filled blisters and erosions on the skin and mucous membranes. We report the series of three cases of bullous pemphigoid in patients of diabetes, who developed bullous pemphigoid after vildagliptin use.","PeriodicalId":49189,"journal":{"name":"the Indian Journal of Pharmacy","volume":"57 5","pages":"350-352"},"PeriodicalIF":1.5000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12419561/pdf/","citationCount":"0","resultStr":"{\"title\":\"A case series of vildagliptin-associated bullous pemphigoid - Rare side effect.\",\"authors\":\"Mohit Kumar Shahi, J V Ashwin, Astha Singh, Suvrat Gupta, K Surya\",\"doi\":\"10.4103/ijp.ijp_522_24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Vildagliptin, among the most commonly used, OHA, belongs to group dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus, has recently been associated with bullous pemphigoid, characterized by fluid-filled blisters and erosions on the skin and mucous membranes. We report the series of three cases of bullous pemphigoid in patients of diabetes, who developed bullous pemphigoid after vildagliptin use.\",\"PeriodicalId\":49189,\"journal\":{\"name\":\"the Indian Journal of Pharmacy\",\"volume\":\"57 5\",\"pages\":\"350-352\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12419561/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"the Indian Journal of Pharmacy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4103/ijp.ijp_522_24\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"the Indian Journal of Pharmacy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/ijp.ijp_522_24","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

维格列汀，在最常用的OHA中，属于二肽基肽酶-4抑制剂组，用于治疗2型糖尿病，最近与大疱性类天疱疮有关，其特征是充满液体的水泡和皮肤和粘膜糜烂。我们报告了三例糖尿病患者的大疱性类天疱疮，他们在使用维格列汀后发生了大疱性类天疱疮。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

A case series of vildagliptin-associated bullous pemphigoid - Rare side effect.

查看原文本刊更多论文

A case series of vildagliptin-associated bullous pemphigoid - Rare side effect.

Vildagliptin, among the most commonly used, OHA, belongs to group dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus, has recently been associated with bullous pemphigoid, characterized by fluid-filled blisters and erosions on the skin and mucous membranes. We report the series of three cases of bullous pemphigoid in patients of diabetes, who developed bullous pemphigoid after vildagliptin use.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

the Indian Journal of Pharmacy Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

3.60

自引率

4.20%

发文量

期刊介绍： Indian Journal of Pharmacology accepts, in English, review articles, articles for educational forum, original research articles (full length and short communications), letter to editor, case reports and interesting fillers. Articles concerning all aspects of pharmacology will be considered. Articles of general interest (e.g. methods, therapeutics, medical education, interesting websites, new drug information and commentary on a recent topic) are also welcome.